Karlowee Vega, Amatya Vishwa Jeet, Hirano Hirofumi, Takayasu Takeshi, Nosaka Ryo, Kolakshyapati Manish, Yoshihiro Masako, Takeshima Yukio, Sugiyama Kazuhiko, Arita Kazunori, Kurisu Kaoru, Yamasaki Fumiyuki
Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Pathobiology. 2017;84(2):99-107. doi: 10.1159/000447951. Epub 2016 Aug 24.
Multicentric gliomas are very rare. Due to differences in their tumor types they remain enigmatic. We focused on the pathogenesis of multicentric gliomas and compared their immunoprofile with that of solitary gliomas. This retrospective study included 6 males and 8 females with multicentric glioma (8 glioblastomas, 2 anaplastic astrocytomas, 4 diffuse astrocytomas). Their age ranged from 27 to 75 years and all were treated between 2004 and June 2015. The expression of mutant isocitrate dehydrogenase 1 (IDH1), α-thalassemia X-linked intellectual disability (ATRX), p53, phosphatase and tensin homolog (PTEN), and epidermal growth factor receptor (EGFR) was examined immunohistochemically; for 1p19q analysis we used fluorescence in situ hybridization (FISH). In all patients, immunohistochemical staining was negative for mutant IDH1 and cytoplasmic PTEN; only 1 patient (7.1%) manifested nuclear PTEN positivity. FISH for 1p19q codeletion was negative in all 9 examined samples; 5 of 14 specimens (35.7%) were p53-positive, 9 (64.3%) were EGFR-positive, and 4 (28.6%) were ATRX-negative. The MIB-1 labeling index was 0.9-15.6% for grades II and III, and ranged between 17.3 and 52.4% for glioblastoma. Our results suggest that the pathogenesis of multicentric gliomas is different from the mutant IDH1-R132H pathogenesis of lower-grade glioma and secondary glioblastomas. More studies are needed to confirm the molecular mechanisms underlying the pathogenesis of multicentric glioma.
多中心胶质瘤非常罕见。由于其肿瘤类型不同,它们仍然是个谜。我们专注于多中心胶质瘤的发病机制,并将其免疫特征与孤立性胶质瘤进行比较。这项回顾性研究纳入了6名男性和8名女性多中心胶质瘤患者(8例胶质母细胞瘤、2例间变性星形细胞瘤、4例弥漫性星形细胞瘤)。他们的年龄在27岁至75岁之间,所有患者均在2004年至2015年6月期间接受治疗。采用免疫组织化学方法检测突变型异柠檬酸脱氢酶1(IDH1)、α地中海贫血伴X连锁智力障碍(ATRX)、p53、磷酸酶和张力蛋白同源物(PTEN)以及表皮生长因子受体(EGFR)的表达;对于1p19q分析,我们使用荧光原位杂交(FISH)。在所有患者中,突变型IDH1和细胞质PTEN的免疫组织化学染色均为阴性;只有1例患者(7.1%)表现为核PTEN阳性。在所有9个检测样本中,1p19q共缺失的FISH检测均为阴性;14个标本中有5个(35.7%)p53阳性,9个(64.3%)EGFR阳性,4个(28.6%)ATRX阴性。II级和III级的MIB-1标记指数为0.9 - 15.6%,胶质母细胞瘤的标记指数在17.3%至52.4%之间。我们的结果表明,多中心胶质瘤的发病机制不同于低级别胶质瘤和继发性胶质母细胞瘤的突变型IDH1-R132H发病机制。需要更多的研究来证实多中心胶质瘤发病机制的分子机制。